HomeFileCoronary disease

Coronary disease

View Category

Acute coronary syndromes

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all...
Dr. Omar Tupayachi -
Learn More
Chronic Ischemic cardiopathy

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR)....
Dr. Andrés Rodríguez -
Learn More
Acute coronary syndromes

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary...
Dr. Andrés Rodríguez -
Learn More
Chronic Ischemic cardiopathy

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However,...
Dr. Omar Tupayachi -
Learn More
Chronic Ischemic cardiopathy

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of...
Dr. Andrés Rodríguez -
Learn More
Acute coronary syndromes

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini...
Dr. Andrés Rodríguez -
Learn More
Coronary disease

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after...
Dr. Juan Manuel Pérez -
Learn More